실시간
BioPharma DiveSensorion, citing Regeneron competition, shifts focus to a different hearing loss therapyEndpoints NewsSummit withdraws $500M offering, citing 'market conditions'Clinical OMICsLipid-Protein Biomarker Makes Clinical Debut with Early Ovarian Cancer DetectionEndpoints NewsSensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophyEndpoints NewsCamurus’ second CRL for acromegaly drug; Teva details workforce cutsFierceBiotechFierce Biotech heading to UK to host event amid London Life Sciences WeekEndpoints NewsBiopharma pay report: Top-paid CSOs, CMOs of 2025Endpoints NewsKardigan plans $320M IPO for heart drugs as Nasdaq listings gain steamPharmaVoiceCompetition is brewing between ADCs and bispecificsBioWorldInnovo Therapeutics synthesizes new NMT1 inhibitorsBioWorldShanghai Qingrun Pharmaceutical Technology patents new Mat2A inhibitorsBioWorldSalubris Pharma reports new RXFP1 receptor agonists
BioWorld 2025년 11월 27일

New YAP1/TEAD interaction inhibitors disclosed in Hansoh patent

New YAP1/TEAD interaction inhibitors disclosed in Hansoh patent

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.